GSK saw its pharmaceutical business decline by 10% in the US due to high competition in the respiratory drugs market. The company's 5-year average 4.90% dividend yield to counter low capital gains.

GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections.

The latest trading session saw GSK (GSK) ending at $41.19, denoting a +0.81% adjustment from its last day's close. The stock lagged the S&P 500's daily gain of 1.11%. Meanwhile, the Dow gained 0.8 ...

GSK lifts long-term sales targets on new drug pipeline It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024.

In the latest trading session, GSK (GSK) closed at $40.80, marking a +0.27% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.74%. Elsewhere, the Dow ...

GSK's native reporting currency is UK pounds, and shares are traded on the London Stock Exchange. GSK ADS, equivalent to 2 GSK shares, are traded on the NYSE in US$. The underlying performance of ...

GSK shares dropped by the most in nearly two years after a ruling by the Delaware State Court that ... GSK GSK fell by 9.5%, its worst single-day performance since the 10.1% decline on Aug. 11 ...

In the latest market close, GSK (GSK) reached $39.88, with a -0.55% movement compared to the previous day. This move lagged the S&P 500's daily loss of 0.37%.

GSK (GSK) ended the recent trading session at $39.64, demonstrating a +1.1% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.41%. At the ...